guest ::
| Home > Publications database > Phase II Study of Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous Cell Carcinoma: Final Analysis. |
| Home > Publications database > Phase II Study of Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous Cell Carcinoma: Final Analysis. |
| Journal Article | DKFZ-2026-02692 |
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ;
2026
American Society of Clinical Oncology
Alexandria, Va.
Abstract: We previously reported the results of a multicenter phase II trial (ClinicalTrials.gov identifier: NCT04154943) of neoadjuvant cemiplimab in resectable stage II to IV cutaneous squamous cell carcinoma (CSCC), in which the pathologic complete response (pCR) rate was 51%. At the 19-month follow-up, estimated 12-month event-free survival (EFS) was 89%, with 11 EFS events. In this study, we report final EFS and overall survival (OS) at a median follow-up of 54 months. Overall, 16 EFS events occurred at final analysis. There were no new disease recurrence events. The five new EFS events were all comorbidity-related deaths without CSCC recurrence. Overall estimated 54-month EFS was 76.2% (81.5% in patients with pCR, 88.9% in patients with major pathologic response, 100% in patients with partial pathologic response, and 45.7% in nonresponders/not-evaluable patients). Among 40 patients with pCR, none had experienced disease recurrence. Overall estimated 54-month OS was 79.4%. No new grade ≥3 treatment-emergent adverse events occurred. The final analysis demonstrates durable EFS and OS, no late recurrences, and no new safety signals with neoadjuvant cemiplimab.
; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Current Contents - Life Sciences ; Essential Science Indicators ; IF >= 40 ; JCR ; Nationallizenz
; PubMed Central ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection
|
The record appears in these collections: |
